US 12,435,039 B2
Activators of caspase-8/c-FLIPL dimerization and their use in cancer therapy
Inna Lavrik, Magdeburg (DE); Laura Hillert, Magdeburg (DE); Nikita Ivanisenko, Magdeburg (DE); and Vladimir Ivanisenko, Magdeburg (DE)
Assigned to Inna Lavrik, Magdeburg (DE)
Appl. No. 17/262,978
Filed by Inna Lavrik, Magdeburg (DE)
PCT Filed Jul. 16, 2019, PCT No. PCT/EP2019/069088
§ 371(c)(1), (2) Date Jan. 25, 2021,
PCT Pub. No. WO2020/020700, PCT Pub. Date Jan. 30, 2020.
Claims priority of application No. 102018118038.1 (DE), filed on Jul. 25, 2018.
Prior Publication US 2022/0363641 A1, Nov. 17, 2022
Int. Cl. C07D 213/56 (2006.01); C07C 311/16 (2006.01); C12Q 1/37 (2006.01); A61P 35/00 (2006.01)
CPC C07D 213/56 (2013.01) [C07C 311/16 (2013.01); C12Q 1/37 (2013.01)] 2 Claims
 
1. A compound, wherein said compound is
2-[[4-(4-pyridyl)benzoyl]amino]ethyl 3-(3-pyridylmethylsulfamoyl)benzoate according to formula III

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.